Mirtafoam 7.5 Tablet contains Mirtazapine 7.5mg, a tetracyclic antidepressant commonly prescribed for major depressive disorder (MDD), anxiety, and related mood disorders. It enhances noradrenergic and serotonergic activity in the brain to improve mood, sleep, and overall mental well-being.
Belonging to the neurology and CNS segment, Mirtafoam 7.5 is recommended for patients experiencing persistent depressive symptoms, sleep disturbances, and anxiety, making it an essential prescription product for psychiatrists and general physicians.
The tablet promotes better adherence and tolerability, allowing gradual dose titration for improved patient outcomes. Its effectiveness in managing depression makes it a high-demand product in hospitals, mental health clinics, and retail pharmacies.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Mirtafoam 7.5 Tablet offers a profitable B2B opportunity in the antidepressant market, with stable demand and strong growth potential across India.